This site uses cookies to provide you with a more responsive and personalised service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page

Health care reform and life sciences: Threat, opportunity or both?


医疗改革与生命科学: 威胁、机遇,或两者并存?In the past, the life sciences industry has been focused on developing the next blockbuster drug or expanding to markets that can offer considerable growth. Now, companies also have to contend with a wave of dramatic changes in many markets: the United States, China, Brazil, Germany, France, the United Kingdom, and other countries have recently passed substantial health care legislation that will have a significant impact on life sciences companies.

This new report published by the Deloitte Global LSHC industry practice in collaboration with The Economist Intelligence Unit analyses the survey findings of 295 senior life sciences industry executives to assess the common elements of the recent wave of global reforms and how life sciences companies are reacting. The paper also explores national differences through case studies of China, Brazil, and Germany.

Share your comments


Stay connected